Despite the controversy of STING agonists in controlling tumor growth in pre-clinical and clinical studies, our findings highlight the use of STING-based immunotherapies for treating cancer pain, especially bone cancer pain, due to multiple actions of the STING pathway in immune modulation, neuromodulation, and neuro-immune interactions (Fig. 10). Here, STING1 is linked to bone neoplasm.